Related Experiment Video

Updated: May 21, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.4K

Comment on "Contraception Use in Adolescents and Young Adults with Congenital Heart Disease"

Syeda Samia Fatima1

  • 1Department of Medicine, Jinnah Sindh Medical University, V22W+F2H، Rafiqui H.J, Iqbal Shaheed Rd, Karachi Cantonment Karachi, Karachi, 75510, Sindh, Pakistan. syedasamiafatimauok@gmail.com.

Pediatric Cardiology
|March 22, 2025
PubMed

Insights

Contraceptive use is low in young adults with congenital heart disease (CHD). Key factors include risks with hormonal contraceptives, menstrual issues, and poor counseling, all impacting reproductive health decisions.

Area of Science:

  • Cardiology
  • Reproductive Health
  • Adolescent Medicine

Background:

  • Adolescents and young adults with congenital heart disease (CHD) exhibit lower contraceptive use rates.
  • This disparity is linked to specific health considerations and healthcare access challenges.

Discussion:

  • Hormonal contraceptives, especially estrogen-based ones, pose risks like thromboembolism and arrhythmias in CHD patients, particularly those with Fontan circulation or transposition of the great arteries.
  • Menstrual irregularities are common in CHD, leading to contraindications for certain contraceptives and potentially discouraging use.
  • Insufficient disease-specific contraceptive counseling creates knowledge gaps, hindering informed reproductive health choices.

Key Insights:

  • Understanding the interplay between CHD physiology and contraceptive risks is crucial.
  • Addressing contraindications and patient-specific needs is essential for safe and effective contraception.
  • Improving counseling enhances informed decision-making and reproductive autonomy.

Outlook:

  • Future research should focus on developing safer contraceptive strategies tailored for CHD populations.
  • Enhanced patient-provider communication and education are vital for optimizing reproductive health outcomes.
  • Long-term studies are needed to evaluate the safety and efficacy of various contraceptive methods in diverse CHD subgroups.

More Related Videos

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training09:15

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training

Published on: February 10, 2022

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K

Related Concept Videos

Birth Control Methods01:22

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
150
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
398
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
695
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
481
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356